Final IMpower030 Results Land at the World Conference on Lung Cancer
Final results from a Phase III lung cancer trial have provided a detailed look at how adding immunotherapy around surgery alters long-term outcomes. In the IMpower030 study, patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) who received perioperative atezolizumab plus platinum-based chemotherapy achieved a median event-free survival of 62.8 months. That compares with 34.9 months for participants who received chemotherapy alone.
The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea. The trial enrolled patients whose tumors were considered resectable, meaning the cancer could be removed surgically — a setting where oncologists increasingly hope that treatment given before and after the operation can reduce the risk of the disease returning.
Beyond the headline event-free survival figure, investigators reported clinically meaningful improvements across several efficacy endpoints. These included event-free survival as assessed by an independent review facility, event-free survival as assessed by investigators, disease-free survival and overall survival. The consistency of the signal across multiple measures is notable, even though the statistical picture is more complicated than the raw numbers alone suggest.
Key Outcomes at a Glance
- Median event-free survival: 62.8 months with perioperative atezolizumab plus chemotherapy versus 34.9 months with placebo plus chemotherapy.
- Pathological complete response: 29.6% versus 8.5%.
- Major pathological response: 53.6% versus 24.4%.
- Surgical cancellations: low and similar between the two treatment groups.
- New safety signals: none identified.
- Endpoint consistency: clinically meaningful improvements reported for independent review facility-assessed event-free survival, investigator-assessed event-free survival, disease-free survival and overall survival.
Why the Statistical Significance Question Matters
One of the most important details in the final analysis is that the trial did not meet its predefined threshold for statistical significance. That is a meaningful caveat, and it is likely to shape how regulators, guideline panels and clinicians interpret the findings. Statistical thresholds in Phase III oncology trials are set in advance to control the risk of declaring a benefit that is actually due to chance, and a trial can fall short of that bar even when the observed difference between arms looks substantial.
In this case, investigators described the improvements as clinically meaningful despite the trial missing that predefined bar. The distinction between statistical significance and clinical meaningfulness is a recurring theme in oncology, particularly in trials where long follow-up, multiple endpoints and heterogeneous patient populations complicate the analysis. For patients and their physicians, the practical question is whether a near-doubling of median event-free survival — and the accompanying jump in pathological response rates — justifies incorporating the regimen into treatment planning.
Pathological Response Offers an Early Signal
The pathological response data may be the most striking part of the presentation. Pathological complete response — the absence of detectable viable tumor cells in the resected specimen after neoadjuvant treatment — reached 29.6% in the atezolizumab arm compared with 8.5% in the control arm. Major pathological response, a broader measure that captures near-complete tumor regression, was recorded in 53.6% of patients receiving the immunotherapy regimen versus 24.4% of those receiving placebo plus chemotherapy.
These figures matter because pathological response is measured directly in tissue removed at surgery, giving a biological readout of how the tumor responded to the treatment delivered before the operation. A regimen that roughly triples the complete response rate compared with chemotherapy alone is doing something meaningful at the level of the tumor, and that biological effect is consistent with the later separation in event-free survival.
Safety, Surgery and Treatment Sequencing
The trial also tracked whether adding immunotherapy interfered with the surgical plan. According to the results, surgical cancellation rates remained low and were similar between the treatment groups — an important finding in a perioperative setting, where the ability to proceed to resection is central to any potential cure.
No new safety signals were identified in the final analysis. However, adverse events occurred more frequently during the neoadjuvant phase of treatment than during the adjuvant phase in both study arms. That pattern suggests the pre-surgical window carries a heavier tolerability burden, something clinicians will need to weigh when counseling patients and scheduling treatment around an operation. Because the finding applies to both arms, it indicates the effect is not unique to the immunotherapy regimen but reflects how intensive pre-operative treatment is delivered in this population.
Investigator Perspective
Dr. Benjamin Solomon of the Peter MacCallum Cancer Center in Melbourne, Australia, who presented the findings, framed the long-term data as supportive of the broader treatment approach. “These long-term findings demonstrate clinically meaningful improvements across several important outcomes and further support the role of perioperative immunotherapy for patients with resectable NSCLC,” he said.
That framing positions the results within a wider shift in thoracic oncology toward treating operable lung cancer with systemic therapy on both sides of surgery, rather than reserving systemic treatment largely for advanced disease.
What This Means for Patients
For someone diagnosed with stage II–IIIB NSCLC that can be surgically removed, the IMpower030 results add evidence that immunotherapy given before and after surgery may extend the time before the cancer returns or progresses. The median event-free survival difference — 62.8 months versus 34.9 months — is large enough to be worth discussing with a care team, particularly alongside the pathological response rates.
At the same time, the failure to meet the predefined significance threshold means the evidence is not unambiguous. Treatment decisions will likely continue to depend on individual factors such as tumor stage, fitness for surgery, tolerance of pre-operative therapy and the specific pathological features of the cancer. Clinicians may also consider how these results sit alongside other perioperative immunotherapy trials in NSCLC.
Open Questions
Several questions remain for the field. How should the borderline statistical picture influence regulatory decisions and guideline recommendations? Which patients derive the greatest benefit from the neoadjuvant versus adjuvant components of the regimen? And how should the higher rate of adverse events during the neoadjuvant phase shape treatment schedules and supportive care?
The Bottom Line
The final IMpower030 analysis delivers a strong signal: in resectable stage II–IIIB NSCLC, perioperative atezolizumab plus platinum-based chemotherapy was associated with a median event-free survival of 62.8 months compared with 34.9 months for chemotherapy alone, along with substantially higher rates of pathological complete and major pathological response, no new safety signals and no increase in surgical cancellations. The trial nonetheless missed its predefined statistical significance threshold, a caveat that will follow these results into clinical discussion. Taken together, the data reinforce the growing role of perioperative immunotherapy in operable lung cancer while leaving room for debate about how the evidence should be weighed.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
